Search results
FDA Expands Pembrolizumab Approval for Endometrial Cancer
Medscape· 14 hours agoThe FDA expanded the approval of pembrolizumab based on improved PFS in patients with advanced or recurrent endometrial cancer in a randomized phase 3 trial.
iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC
Clinical Trials Arena via Yahoo Finance· 9 hours agoThe double-blind, placebo-controlled study aims to compare the combination of belrestotug and...
EXCLUSIVE: Woman, 64, diagnosed with cancer in knee after several doctors dismissed her first...
TODAY via Yahoo News· 22 hours agoHer treatment plan included five days of radiation for five weeks and then surgery to remove the...
Subtle victory for Sanders in Novo spat
Politico· 3 hours agoThe FDA approved Merck’s Keytruda with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adults with primary advanced or recurrent endometrial cancer ...
Moderna Stock (NASDAQ:MRNA): Is There Life Beyond Disease Outbreaks?
TipRanks via Yahoo Finance· 23 hours agoModerna (NASDAQ:MRNA) stock has surged 40.8% since the turn of the year. Some of this momentum can...
Could British Columbia Eliminate Cervical Cancer by 2031?
Medscape· 7 days agoMoving from cytology to HPV-based screening could speed the process of eliminating cervical cancer...
NHS genomics testing will be vital in supporting personalised cancer trials
Clinical Trials Arena via Yahoo Finance· 4 days agoThe second trial, which has been recently launched by the NHS in collaboration with BioNTech, is...
Baysient® Launches Therapeutic Drug Monitoring Software for Oncology Biologics
Benzinga· 10 hours agoBaysient®, a leading provider of therapeutic drug monitoring (TDM) software, today announced the launch of TuMinimize™, a web-based nomogram/algorithm designed to optimize the dosing of oncology ...
J&J-backed Bright Peak secures $90m to advance immunoconjugate programme
Pharmaceutical Technology via Yahoo Finance· 6 days agoThe PD-1 inhibitor landscape is currently dominated by MSD’s Keytruda (pembrolizumab) and Bristol...
